TYMS
Reaktivität: Human
WB, IHC, ELISA, IHC (p), IP
Wirt: Maus
Monoclonal
2B2
unconjugated
Applikationshinweise
The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the Thymidylate synthase antibody to be titered up or down for optimal performance.
1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
1 mg/mL
Buffer
1 mg/mL in 1X PBS, BSA free, sodium azide free
Konservierungsmittel
Azide free
Lagerung
4 °C,-20 °C
Informationen zur Lagerung
Store the Thymidylate synthase antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).
Target
TYMS
(Thymidylate Synthetase (TYMS))
Andere Bezeichnung
Thymidylate Synthase
Hintergrund
Thymidylate synthase converts deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP), which is essential for DNA biosynthesis. Thymidylate synthase is also a critical target for the fluoropyrimidines, an important group of anti-neoplastic drugs that are widely used in the treatment of solid tumors. Both 5-FU and fluorodeoxyuridine are converted in tumor cells to FdUMP which inactivates thymidylate synthase by formation of a ternary covalent complex in the presence of the folate cofactor 5,10-methylenetetrahydrofolate. Expression of thymidylate synthase protein is associated with response to 5-fluorouracil (5-FU) in human colorectal, gastric, head and neck, and breast carcinomas.